2-[(2-oxopropyl)thio] imidazolium derivates

This class of non-peptidyl, active site directed molecules was developed by Merck Sharp & Dohme in the 1990s. The active site cysteinyl residue attacks the carbonyl group (1) similar to the glutamine residue. However, the subsequent reaction leads to the release of the complementary thione (2) and to the acetonylation of the cysteine (3) (Freund et al., Biochemistry 1994, 33:10109-19).

Even if the molecules were developed to block coagulation factor XIIIa, the compounds inhibit tissue transglutaminase as well (Barsigan et al., J. Biol. Chem. 1991, 22501-9).

One candidate out of the series has been evaluated in animal models (e.g. Shebuski et al., blood 1990, 1455-9). Please notice that the authors reported a plasma half life of 5 to 10 minutes only.

Oxopropyl thio imidazolium derivates mechanism

Zedira offers three derivatives of the thioimidazolium scaffold.

T101 (L-682.777) is a good blocker of tissue transglutaminase and coagulation factor XIIIa. Both enzymes are inhibited with an IC50 of about 0.25 μM.

     D004 (L-683.685) is a good blocker of tissue transglutaminase and coagulation factor XIIIa. Both enzymes are blocked with an IC50 of about 0.35 μM.

D003 is a weak blocker of tissue transglutaminase with an IC50 of about 1.0 μM.

Art. No.
D003 1,3-Dimethyl-2-[(2-oxopropyl)thio]imidazolium chloride
100 mg
480 €
D004 1,3-Dimethyl-4,5-diphenyl-2-[(2-oxopropyl)thio]imidazolium trifluorosulfonic acid salt
10 mg
520 €
T101 1,3,4,5-Tetramethyl-2-[(2-oxopropyl)thio]imidazolium chloride
10 mg
480 €

  • News  

    • Press release: Dr. Falk Pharma and Zedira announce completion of phase 1b clinical trial of ZED1227 for the treatment of celiac disease and move on to proof of concept study
    • Pressemitteilung: Dr. Falk Pharma und Zedira geben den Abschluss der Phase 1b-Studie für ZED1227 zur Zöliakie-Therapie bekannt und planen Start der Wirksamkeitsstudie
  • Blog

  • Events  

    • 17th International Celiac Disease Symposium

      08.09.2017 - 10.09.2017
      New Delhi, India

    • NLSDays 2017

      12.09.2017 - 14.09.2017
      Malmö, Sweden

    • BIO-Europe

      06.11.2017 - 08.11.2017
      Berlin, Germany

    • MEDICA

      13.11.2017 - 16.11.2017
      Düsseldorf, Germany

    • Gordon Research Conference on: Transglutaminases in Human Disease Processes

      16.06.2018 - 17.06.2018
      Les Diablerets, Switzerland